Skip to main content
SpringerLink
Log in

Chronic Myeloid Leukemia

  • Chapter
  • First Online:
Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics

Part of the book series: Cancer Growth and Progression ((CAGP,volume 14))

  • 1320 Accesses

Abstract

It is estimated that 4,870 new cases of chronic myeloid leukemia (CML) will be diagnosed in 2010, representing approximately 11 % of all leukemias (Jemal et al. 2010). The median age of diagnosis reported in 2003–2007 was 65 years of age (Altekruse et al. 2010). The etiology of CML remains unclear; evidence is lacking demonstrating hereditary influence. Individuals who have been exposed to ionizing radiation or benzene are at an increase risk of developing CML (Corso et al. 1995). Other risk factors which have been evaluated include smoking, benzene, and magnetic field exposure (Bjork et al. 2001; Hayes et al. 1997; Kheifets et al. 1997). To date, these are all inconclusive in correlating exposure to acquisition of CML. A recent M.D. Anderson study suggests that adulthood obesity and occupational exposure to agricultural chemicals increase CML risk (Strom et al. 2009).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Abdelhalim A, Barcos M, Block AW et al (2007) Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy. Leuk Lymphoma 48:1053–1056

    Article  PubMed  CAS  Google Scholar 

  • Aguayo A, Couban S (2009) State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment. Leuk Lymphoma 50(Suppl 2):1–8

    Article  PubMed  CAS  Google Scholar 

  • Altekruse SF, Kosary C, Krapcho M, Neyman N (2010) SEER cancer statistics review 1975–2007. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2007/

    Google Scholar 

  • Baccarani M, Cortes J, Pane F et al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041–6051

    Article  PubMed  CAS  Google Scholar 

  • Barnes DJ, Palaiologou D, Panousopoulou E et al (2005) Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 65:8912–8919

    Article  PubMed  CAS  Google Scholar 

  • Baskaran R, Wood LD, Whitaker LL et al (1997) Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 387:516–519

    Article  PubMed  CAS  Google Scholar 

  • Bergeron A, Rea D, Levy V et al (2007) Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 176:814–818

    Article  PubMed  CAS  Google Scholar 

  • Bhatia R, Holtz M, Niu N et al (2003) Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101:4701–4707

    Article  PubMed  CAS  Google Scholar 

  • Biggs JC, Szer J, Crilley P et al (1992) Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 80:1352–1357

    PubMed  CAS  Google Scholar 

  • Bjork J, Albin M, Welinder H et al (2001) Are occupational, hobby, or lifestyle exposures associated with Philadelphia chromosome positive chronic myeloid leukaemia? Occup Environ Med 58:722–727

    Article  PubMed  CAS  Google Scholar 

  • Boehm A, Walcherberger B, Sperr WR et al (2011) Improved outcome in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: a single center experience. Biol Blood Marrow Transplant 17:133–140

    Google Scholar 

  • Borthakur G, Kantarjian H, Daley G et al (2006) Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 106:346–352

    Article  PubMed  CAS  Google Scholar 

  • Branford S, Rudzki Z, Parkinson I et al (2004) Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 104:2926–2932

    Article  PubMed  CAS  Google Scholar 

  • Breccia M, Alimena G (2009) Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem. Cardiovasc Hematol Disord Drug Targets 9:21–28

    Article  PubMed  CAS  Google Scholar 

  • Breccia M, Palandri F, Iori AP et al (2010) Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. Leuk Res 34:143–147

    Article  PubMed  CAS  Google Scholar 

  • Canitrot Y, Falinski R, Louat T et al (2003) p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood 102:2632–2637

    Article  PubMed  CAS  Google Scholar 

  • Clift RA, Buckner CD, Thomas ED et al (1994) Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood 84:4368–4373

    PubMed  CAS  Google Scholar 

  • Cohen MH, Williams G, Johnson JR et al (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:935–942

    PubMed  CAS  Google Scholar 

  • Conchon M, Sanabani SS, Bendit I, Santos FM, Serpa M, Dorliac-Llacer PE (2009) Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. J Hematol Oncol 2:42

    Article  PubMed  CAS  Google Scholar 

  • Conchon M, Sanabani SS, Serpa M et al (2010) Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy. Adv Hematol 2010:136252

    PubMed  Google Scholar 

  • Corso A, Lazzarino M, Morra E et al (1995) Chronic myelogenous leukemia and exposure to ionizing radiation–a retrospective study of 443 patients. Ann Hematol 70:79–82

    Article  PubMed  CAS  Google Scholar 

  • Cortes J, O’Brien S, Kantarjian H (2004) Discontinuation of imatinib therapy after achieving a molecular response. Blood 104:2204–2205

    Article  PubMed  CAS  Google Scholar 

  • Cortes J, Giles F, Salvado AJ, McDougall K (2006) Molecular responses in newly diagnosed chronic myelocytic leukemia (CML) patients treated with 800 mg imatinib daily. An update from the RIGHT trial study group. Blood 108:2149

    Google Scholar 

  • Cortes J, Rousselot P, Kim DW et al (2007a) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109:3207–3213

    Article  PubMed  CAS  Google Scholar 

  • Cortes J, Quintas-Cardama A, Garcia-Manero G et al (2007b) Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer 110:2000–2006

    Article  PubMed  CAS  Google Scholar 

  • Cortes JE, O’brien SM, Ferrajoli A, Borthakur G (2008) Efficacy of nilotinib (AMN107) in patients (Pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)- positive chronic myelogenous leukemia in early chronic phase (CML-CP). J Clin Oncol 26:7016

    Article  Google Scholar 

  • Cortes JE, Jones D, O’Brien S et al (2010a) Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28:398–404

    Article  PubMed  CAS  Google Scholar 

  • Cortes JE, Jones D, O’Brien S et al (2010b) Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 28:392–397

    Article  PubMed  CAS  Google Scholar 

  • Cortes-Franco J, Raghunadharao D, Parikh S, Wetzler M (2009) Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors – Results of a multicenter phase 2/3 study. Blood (ASH Annual Meeting Abstracts) 114:861

    Google Scholar 

  • de Lavallade H, Punnialingam S, Milojkovic D et al (2008) Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 141:745–747

    Article  PubMed  Google Scholar 

  • Deininger M, O’brien SG, Guilhot F (2009) International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 114:1126

    Google Scholar 

  • deKlein A, Van Kessel AG, Grosveld G, Bartram CR (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300:765–767

    Article  CAS  Google Scholar 

  • Doyle LA, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340–7358

    Article  PubMed  CAS  Google Scholar 

  • Druker BJ, Tamura S, Buchdunger E et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561–566

    Article  PubMed  CAS  Google Scholar 

  • Druker BJ, Talpaz M, Resta DJ et al (2001a) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037

    Article  PubMed  CAS  Google Scholar 

  • Druker BJ, Sawyers CL, Kantarjian H et al (2001b) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038–1042

    Article  PubMed  CAS  Google Scholar 

  • Druker BJ, Guilhot F, O’Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408–2417

    Article  PubMed  CAS  Google Scholar 

  • Drummond M, Lennard A, Brummendorf T, Holyoake T (2004) Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia. Leuk Lymphoma 45:1775–1781

    Article  PubMed  CAS  Google Scholar 

  • Fialkow PJ, Jacobson RJ, Papayannopoulou T (1977) Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 63:125–130

    Article  PubMed  CAS  Google Scholar 

  • Fiskus W, Pranpat M, Bali P et al (2006a) Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 108:645–652

    Article  PubMed  CAS  Google Scholar 

  • Fiskus W, Pranpat M, Balasis M et al (2006b) Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res 12:5869–5878

    Article  PubMed  CAS  Google Scholar 

  • Frigeri F, Arcamone M, Luciano L, Di Francia R, Pane F, Pinto A (2009) Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia. Blood 113:5028–5029

    Article  PubMed  CAS  Google Scholar 

  • Furstoss O, Dorey K, Simon V, Barila D, Superti-Furga G, Roche S (2002) c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis. EMBO J 21:514–524

    Article  PubMed  CAS  Google Scholar 

  • Garg RJ, Kantarjian H, O’Brien S et al (2009) The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 114:4361–4368

    Article  PubMed  CAS  Google Scholar 

  • Garland P, Dazzi F, Marin D (2010) Dasatinib may not suppress the GVL effect of donor lymphocyte infusions for CML. Bone Marrow Transplant 45:395–396

    Article  PubMed  CAS  Google Scholar 

  • Giles F, Le Coutre P, Bhalla K (2007) A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase, accelerated phase, or blast crisis who also failed dasatinib. J Clin Oncol 25:7038

    Google Scholar 

  • Giles F, Larson R, Kantarjian H (2008) Nilotinib in chronic myelogenous leukemia in blast crisis (CML-BC) patients with imatinib resistance or intolerance: update of a phase 2 results. 13th Congress of the European Hematology Association (EHA), Copenhagen

    Google Scholar 

  • Goff SP, Gilboa E, Witte ON, Baltimore D (1980) Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: studies with cloned viral DNA. Cell 22:777–785

    Article  PubMed  CAS  Google Scholar 

  • Goldblatt M, Huggins JT, Doelken P, Gurung P, Sahn SA (2009) Dasatinib-induced pleural effusions: a lymphatic network disorder? Am J Med Sci 338:414–417

    Article  PubMed  Google Scholar 

  • Gorre ME, Mohammed M, Ellwood K et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876–880

    Article  PubMed  CAS  Google Scholar 

  • Graham SM, Jorgensen HG, Allan E et al (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99:319–325

    Article  PubMed  CAS  Google Scholar 

  • Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36:93–99

    Article  PubMed  CAS  Google Scholar 

  • Guilhot F, Apperley J, Kim DW et al (2007) Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109:4143–4150

    Article  PubMed  CAS  Google Scholar 

  • Hayes RB, Yin SN, Dosemeci M et al (1997) Benzene and the dose-related incidence of hematologic neoplasms in China. Chinese Academy of Preventive Medicine–National Cancer Institute Benzene Study Group. J Natl Cancer Inst 89:1065–1071

    Article  PubMed  CAS  Google Scholar 

  • He Y, Wertheim JA, Xu L et al (2002) The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood 99:2957–2968

    Article  PubMed  CAS  Google Scholar 

  • He K, Lago MW, Iyer RA, Shyu WC, Humphreys WG, Christopher LJ (2008) Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metab Dispos 36:2564–2570

    Article  PubMed  CAS  Google Scholar 

  • Hidaka H, Inagaki M, Kawamoto S, Sasaki Y (1984) Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 23:5036–5041

    Article  PubMed  CAS  Google Scholar 

  • Hochhaus A, Kantarjian HM, Baccarani M et al (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303–2309

    Article  PubMed  CAS  Google Scholar 

  • Hochhaus A, Muller MC, Radich J et al (2009) Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia 23:1628–1633

    Article  PubMed  CAS  Google Scholar 

  • Holtz MS, Forman SJ, Bhatia R (2005) Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 19:1034–1041

    Article  PubMed  CAS  Google Scholar 

  • Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S (2006) Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+  leukemia in mice. Proc Natl Acad Sci USA 103:16870–16875

    Article  PubMed  CAS  Google Scholar 

  • Hughes TP, Branford S (2009) Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reaction. Clin Lymphoma Myeloma 9(Suppl 3):S266–271

    Article  PubMed  CAS  Google Scholar 

  • Jabbour E, Kantarjian H, Jones D et al (2006a) Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20:1767–1773

    Article  PubMed  CAS  Google Scholar 

  • Jabbour E, Kantarjian H, Giles F, O’Brien S (2006b) Treatment with nilotinib for patients with chronic myeloid leukemia (CML) who failed prior therapy with imatinib and dasatinib. Blood 108:2171

    Article  CAS  Google Scholar 

  • Jabbour E, Cortes J, Kantarjian H et al (2007) Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 110:340–344

    Article  PubMed  CAS  Google Scholar 

  • Jain SK, Susa M, Keeler ML, Carlesso N, Druker B, Varticovski L (1996) PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl. Blood 88:1542–1550

    PubMed  CAS  Google Scholar 

  • Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60:277–300

    Article  PubMed  Google Scholar 

  • Kadia TM, Yang H, Ferrajoli A et al (2010) A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol 150:72–82

    PubMed  CAS  Google Scholar 

  • Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M (1993) Chronic myelogenous leukemia: a concise update. Blood 82:691–703

    PubMed  CAS  Google Scholar 

  • Kantarjian H, Sawyers C, Hochhaus A et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645–652

    Article  PubMed  CAS  Google Scholar 

  • Kantarjian H, Giles F, Wunderle L et al (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542–2551

    Article  PubMed  Google Scholar 

  • Kantarjian H, Pasquini R, Hamerschlak N et al (2007a) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109:5143–5150

    Article  PubMed  CAS  Google Scholar 

  • Kantarjian HM, Giles F, Gattermann N et al (2007b) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540–3546

    Article  PubMed  CAS  Google Scholar 

  • Kantarjian H, Pasquini R, Levy V et al (2009a) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 115:4136–4147

    Article  PubMed  CAS  Google Scholar 

  • Kantarjian H, Cortes J, Kim DW et al (2009b) Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 113:6322–6329

    Article  PubMed  CAS  Google Scholar 

  • Kantarjian HM, Giles FJ, Bhalla KN, Larson R (2009c) Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: Clinical response, safety, and long-term outcomes. Blood 114:1129

    Google Scholar 

  • Kantarjian H, Shah N, Hochhaus A, Cortes J (2010a) Dasatinib compared to imatinib(IM) in patients with newly diagnosed chronic phase chronic myelogenous leukemia (CML-CP): twleve month efficacy and safety from the phase III DASISION study. J Clin Oncol 28:LBA6500

    Google Scholar 

  • Kantarjian H, Shah NP, Hochhaus A et al (2010b) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260–2270

    Article  PubMed  CAS  Google Scholar 

  • Keller G, Brassat U, Braig M, Heim D, Wege H, Brummendorf TH (2009) Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy. Hematol Oncol 27:123–129

    Article  PubMed  CAS  Google Scholar 

  • Kharas MG, Fruman DA (2005) ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 65:2047–2053

    Article  PubMed  CAS  Google Scholar 

  • Kharas MG, Deane JA, Wong S et al (2004) Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood 103:4268–4275

    Article  PubMed  CAS  Google Scholar 

  • Kheifets LI, Afifi AA, Buffler PA, Zhang ZW, Matkin CC (1997) Occupational electric and magnetic field exposure and leukemia. A meta-analysis. J Occup Environ Med 39:1074–1091

    Article  PubMed  CAS  Google Scholar 

  • Klyuchnikov E, Kroger N, Brummendorf TH, Wiedemann B, Zander AR, Bacher U (2010) Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML). Biol Blood Marrow Transplant 16:301–310

    Article  PubMed  CAS  Google Scholar 

  • Kroger N, Bacher U, Bader P et al (2010) NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant 16:1325–1346

    Article  PubMed  Google Scholar 

  • Kurzrock R, Gutterman JU, Talpaz M (1988) The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319:990–998

    Article  PubMed  CAS  Google Scholar 

  • Lahaye T, Riehm B, Berger U et al (2005) Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 103:1659–1669

    Article  PubMed  Google Scholar 

  • Larson RA, Druker BJ, Guilhot F et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022–4028

    Article  PubMed  CAS  Google Scholar 

  • Laurent E, Talpaz M, Kantarjian H, Kurzrock R (2001) The BCR gene and philadelphia chromosome-positive leukemogenesis. Cancer Res 61:2343–2355

    PubMed  CAS  Google Scholar 

  • Le Coutre P, Ottmann OG, Giles F et al (2008a) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111:1834–1839

    Article  PubMed  CAS  Google Scholar 

  • Le Coutre P, Giles F, Hochhaus A, Apperley J (2008b) Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 2 year follow-up results from a Phase 2 study. Blood 112:3229

    Google Scholar 

  • Le Coutre P, O’Dwyer E, Mendes L (2008c) The occurence of pleural/pericardial effusions in Ph+CML patients failing prior tyrosine kinase inhibitors (TKI) before starting nilotinib- Analysis of data from compassionate use program. 13th Congress of the European Hematology Association (EHA), Copenhagen, p 0557

    Google Scholar 

  • Liu J, Joha S, Idziorek T et al (2008) BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. Leukemia 22:791–799

    Article  PubMed  CAS  Google Scholar 

  • Mahon FX, Deininger MW, Schultheis B et al (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96:1070–1079

    PubMed  CAS  Google Scholar 

  • Mahon FX, Belloc F, Lagarde V et al (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101:2368–2373

    Article  PubMed  CAS  Google Scholar 

  • Maru Y, Witte ON (1991) The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell 67:459–468

    Article  PubMed  CAS  Google Scholar 

  • Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A (2009) Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 43:967–968

    Article  PubMed  CAS  Google Scholar 

  • McWhirter JR, Galasso DL, Wang JY (1993) A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 13:7587–7595

    PubMed  CAS  Google Scholar 

  • Melo JV (1996) The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88:2375–2384

    PubMed  CAS  Google Scholar 

  • Melo JV, Deininger MW (2004) Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation. Hematol Oncol Clin North Am 18:545–568, vii–viii

    Article  PubMed  Google Scholar 

  • Melo JV, Myint H, Galton DA, Goldman JM (1994) P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia 8:208–211

    PubMed  CAS  Google Scholar 

  • Menzel H, von Bubnoff N, Hochhaus A, Haferlach C, Peschel C, Duyster J (2007) Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib. Bone Marrow Transplant 40:83–84

    Article  PubMed  CAS  Google Scholar 

  • Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, Lazzarino M (2005) Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90:979–981

    PubMed  Google Scholar 

  • Merante S, Colombo AA, Calatroni S et al (2009) Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation. Bone Marrow Transplant 44:263–264

    Article  PubMed  CAS  Google Scholar 

  • Misaghian N, Ligresti G, Steelman LS et al (2009) Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 23:25–42

    Article  PubMed  CAS  Google Scholar 

  • Nakahara F, Sakata-Yanagimoto M, Komeno Y et al (2010) Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. Blood 115:2872–2881

    Article  PubMed  CAS  Google Scholar 

  • National Comprehensive Cancer Network clincal practice guidelines in oncology (2010) Chronic myelogenous leukemia, retrieved 8-07-2012 http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf

  • Noens L, van Lierde MA, De Bock R et al (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113:5401–5411

    Article  PubMed  CAS  Google Scholar 

  • Novartis Pharmaceuticals Corporation (2010) Package insert. Tasigna (nilotinib). Novartis Pharmaceuticals Corporation, East Hanover

    Google Scholar 

  • Nowell PC, Hungerfold DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132:1497–1501

    Google Scholar 

  • O’Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004

    Article  PubMed  Google Scholar 

  • Oweini H, Otrock ZK, Mahfouz RA, Bazarbachi A (2011) Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib. Arch Gynecol Obstet 283:133–134

    Article  PubMed  Google Scholar 

  • Pane F, Frigeri F, Sindona M et al (1996) Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 88:2410–2414

    PubMed  CAS  Google Scholar 

  • Pendergast AM (2002) The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res 85:51–100

    Article  PubMed  CAS  Google Scholar 

  • Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON (1991) BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 66:161–171

    Article  PubMed  CAS  Google Scholar 

  • Pendergast AM, Quilliam LA, Cripe LD et al (1993) BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175–185

    PubMed  CAS  Google Scholar 

  • Porkka K, Koskenvesa P, Lundan T et al (2008) Dasatinib crosses the blood–brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 112:1005–1012

    Article  PubMed  CAS  Google Scholar 

  • Press RD, Galderisi C, Yang R et al (2007) A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 13:6136–6143

    Article  PubMed  CAS  Google Scholar 

  • Quintas-Cardama A, Cortes J (2009) Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113:1619–1630

    Article  PubMed  CAS  Google Scholar 

  • Quintas-Cardama A, Kantarjian H, Jones D et al (2007a) Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 109:497–499

    Article  PubMed  CAS  Google Scholar 

  • Quintas-Cardama A, Kantarjian H, O’Brien S et al (2007b) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25:3908–3914

    Article  PubMed  CAS  Google Scholar 

  • Quintas-Cardama A, Kantarjian H, Cortes J (2007c) Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 6:834–848

    Article  PubMed  CAS  Google Scholar 

  • Radich JP, Gooley T, Bensinger W et al (2003) HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 102:31–35

    Article  PubMed  CAS  Google Scholar 

  • Rasheed W, Flaim B, Seymour JF (2009) Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 33:861–864

    Article  PubMed  Google Scholar 

  • Robinson DR, Wu YM, Lin SF (2000) The protein tyrosine kinase family of the human genome. Oncogene 19:5548–5557

    Article  PubMed  CAS  Google Scholar 

  • Ross DM, Branford S, Moore S, Hughes TP (2006) Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia 20:664–670

    Article  PubMed  CAS  Google Scholar 

  • Rousselot P, Huguet F, Rea D et al (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109:58–60

    Article  PubMed  CAS  Google Scholar 

  • Rowley JD (1973) A new consistent chromosome abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:209–213

    Article  Google Scholar 

  • Roy A, Shah N, Le Coutre P, Wang X (2010) Relationship between dasatinib exposure and long term clinical outcomes in chronic phase chronic myleoid leukemia (CML-CP) patients. J Clin Oncol 28:6518

    Google Scholar 

  • Saglio G, Kim DW, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251–2259

    Article  PubMed  CAS  Google Scholar 

  • Sattler M, Verma S, Shrikhande G et al (2000) The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 275:24273–24278

    Article  PubMed  CAS  Google Scholar 

  • Sattler M, Mohi MG, Pride YB et al (2002) Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1:479–492

    Article  PubMed  CAS  Google Scholar 

  • Savage DG, Szydlo RM, Chase A, Apperley JF, Goldman JM (1997) Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol 99:30–35

    Article  PubMed  CAS  Google Scholar 

  • Sawyers CL, McLaughlin J, Goga A, Havlik M, Witte O (1994) The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell 77:121–131

    Article  PubMed  CAS  Google Scholar 

  • Sawyers CL, Hochhaus A, Feldman E et al (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530–3539

    Article  PubMed  CAS  Google Scholar 

  • Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938–1942

    Article  PubMed  CAS  Google Scholar 

  • Shah NP, Kim DW, Kantarjian H et al (2010a) Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 95:232–240

    Article  PubMed  CAS  Google Scholar 

  • Shah N, Cortes J, Schiffer A, Coutre P (2010b) Four year follow-up of patients with chronic phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily. J Clin Oncol 28:6512

    Article  Google Scholar 

  • Shimoni A, Leiba M, Schleuning M et al (2009) Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia. Leukemia 23:190–194

    Article  PubMed  CAS  Google Scholar 

  • Sirard C, Lapidot T, Vormoor J et al (1996) Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood 87:1539–1548

    PubMed  CAS  Google Scholar 

  • Smith DC, Britten C, DON Clary LT (2009) A phase I study of XL228, a potent IGF1R/AURORA/SRC inhibitor, in patients with solid tumors or hematologic malignancies. J Clin Oncol 27:3512

    Google Scholar 

  • Sokal JE, Baccarani M, Russo D, Tura S (1988) Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 25:49–61

    PubMed  CAS  Google Scholar 

  • Spencer A, Prince M, Deangelo D (2007) Phase IA/II study of oral LBH589, a novel deactylase inhibitor (DACi), administered on 2 schedules, in patients with advanced hematologic malignancies. Blood 110:1041

    Google Scholar 

  • Stoklosa T, Poplawski T, Koptyra M et al (2008) BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res 68:2576–2580

    Article  PubMed  CAS  Google Scholar 

  • Strom SS, Yamamura Y, Kantarijian HM, Cortes-Franco JE (2009) Obesity, weight gain, and risk of chronic myeloid leukemia. Cancer Epidemiol Biomarkers Prev 18:1501–1506

    Article  PubMed  Google Scholar 

  • Talpaz M, Silver RT, Druker BJ et al (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99:1928–1937

    Article  PubMed  CAS  Google Scholar 

  • Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531–2541

    Article  PubMed  CAS  Google Scholar 

  • Varticovski L, Daley GQ, Jackson P, Baltimore D, Cantley LC (1991) Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol 11:1107–1113

    PubMed  CAS  Google Scholar 

  • Velev N, Cortes J, Champlin R et al (2010) Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer 116(15):3631–3637

    Article  PubMed  CAS  Google Scholar 

  • Wang L, Knight K, Lucas C, Clark RE (2006) The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica 91:235–239

    PubMed  CAS  Google Scholar 

  • Welch PJ, Wang JY (1993) A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. Cell 75:779–790

    Article  PubMed  CAS  Google Scholar 

  • White DL, Saunders VA, Dang P et al (2007) Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110:4064–4072

    Article  PubMed  CAS  Google Scholar 

  • Yaish P, Gazit A, Gilon C, Levitzki A (1988) Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242:933–935

    Article  PubMed  CAS  Google Scholar 

  • Zhao C, Chen A, Jamieson CH et al (2009) Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458:776–779

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Kansas Medical Center, Kansas City, KS, USA

    Kapil Bhalla, Celalettin Ustun & Warren Fiskus

Authors
  1. Kapil Bhalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Celalettin Ustun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Warren Fiskus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kapil Bhalla .

Editor information

Editors and Affiliations

  1. Research Institute, Department of Hematopathology and, H. Lee Moffitt Cancer Center &, Magnolia Drive - MCC-LAB 12902, Tampa, 33612, Florida, USA

    Jianguo Tao

  2. Research Institute, Department of Malignant Hematology, H. Lee Moffitt Cancer Center &, Magnolia Drive 12902, Tampa, 33612, Florida, USA

    Eduardo Sotomayor

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Bhalla, K., Ustun, C., Fiskus, W. (2012). Chronic Myeloid Leukemia. In: Tao, J., Sotomayor, E. (eds) Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics. Cancer Growth and Progression, vol 14. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-5028-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-94-007-5028-9_13

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-007-5027-2

  • Online ISBN: 978-94-007-5028-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation